64010-39-5 Usage
Appearance
Clear, colorless liquid It is a transparent liquid without any color, making it difficult to see without proper lighting.
Molecular weight
241.53 g/mol The total mass of one mole of 1-bromo-2-(3-chloropropoxy)benzene is 241.53 grams.
Usage
Intermediate in synthesis It is used as an intermediate compound in the production of pharmaceuticals, agrochemicals, and other organic compounds.
Application
Building block in specialty chemicals It serves as a fundamental component in the creation of various specialty chemicals.
Versatility
Numerous applications in chemistry and industry 1-bromo-2-(3-chloropropoxy)benzene has a wide range of uses across different fields, making it a valuable asset in research and development.
Safety precautions
Handle with care Due to its potential hazards, it is essential to follow proper safety measures when working with 1-bromo-2-(3-chloropropoxy)benzene to prevent accidents and ensure a safe working environment.
Check Digit Verification of cas no
The CAS Registry Mumber 64010-39-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,4,0,1 and 0 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 64010-39:
(7*6)+(6*4)+(5*0)+(4*1)+(3*0)+(2*3)+(1*9)=85
85 % 10 = 5
So 64010-39-5 is a valid CAS Registry Number.
64010-39-5Relevant academic research and scientific papers
COMPOUNDS USEFUL AS IMMUNOMODULATORS
-
Paragraph 0642; 0643, (2017/05/07)
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS
-
Page column 189, (2010/02/06)
This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therepeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
